Changes in adrenoceptors and G-protein-coupled receptor kinase 2 in L-NAME-induced hypertension compared to spontaneous hypertension in rats

Journal of Vascular Research

Volumn 51, Issue 3, 2014, Pages 209-220

  Oliver, Eduardo ^a   Flacco, Nicla ^a   Arce, Cristina ^a   Ivorra, M Dolores ^a   D'Ocon, M Pilar ^a   Noguera, M Antonia ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Adrenoceptors; Aorta; G protein coupled receptor kinase 2; Hypertension; Mesenteric resistance arteries

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; AMIBEGRON; BETA 1 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; ISOPRENALINE; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; SALBUTAMOL; ADRENERGIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR SYSTEM; COMPARATIVE STUDY; CONDUCTANCE; CONTROLLED STUDY; DRUG POTENCY; ESSENTIAL HYPERTENSION; HEART CONTRACTION; HEART MUSCLE CONTRACTILITY; HYPERTENSION; IMMUNOBLOTTING; LONG TERM CARE; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RESISTANCE BLOOD VESSEL; SENSITIVITY ANALYSIS; VASOCONSTRICTION; VASODILATATION; MUSCLE CONTRACTILITY; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; AORTA; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HYPERTENSION; MALE; MESENTERIC ARTERIES; NG-NITROARGININE METHYL ESTER; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-2; VASOCONSTRICTION; VASODILATION;

EID: 84902300634     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000360400     Document Type: Article

References (48)

1. Kunes J, Hojna S, Kadlecova M, Dobešova Z,Rauchova H, Vokurkova M, Loukotova J,Pecha?ova O, Zicha J: Altered balance of vasoactivesystems in experimental hypertension: The role of relative NO deficiency. PhysiolRes 2004; 53:S23-S34.
2. Torok J: Participation of nitric oxide in differentmodels of experimental hypertension. Physiol Res 2008; 57: 813-825.
3. Harris DM, Cohn HI, Pesant S, Eckhart AD:GPCR signaling in hypertension: role ofGRKs. Clin Sci 2008; 115: 79-89.
4. Penela P, Murga C, Ribas C, Tutor AS, PeregrinS, Mayor F Jr: Mechanisms of regulationof G protein-coupled receptor kinases (GRKs)and cardiovascular disease. Cardiovasc Res2006; 69: 46-56.
5. Premont RT, Gainetdinov RR: Physiologicalroles of G protein-coupled receptor kinasesand arrestins. Annu Rev Physiol 2007; 69:511-534.
6. Pitcher JA, Freedman NJ, Lefkowitz RJ: Gprotein-coupled receptor kinases. Annu RevBiochem 1998; 67: 653-692.
7. Ferguson SS: Evolving concepts in G-proteincoupledreceptor endocytosis: the role in desensitizationand signaling. Pharmacol Rev2001; 53: 1-24.
8. Eckhart AD, Ozaki T, Tevaearai H, RockmanHA, Koch WJ: Vascular targeted overexpressionof G protein-coupled receptor kinase-2in transgenic mice attenuates beta-Adrenergicreceptor signaling and increases resting bloodpressure. Mol Pharmacol 2002; 61: 749-758.
9. Schutzer WE, Xue H, Reed J, Oyama T, BeardDR, Anderson S, Mader SL: Age-relatedβ-Adrenergic receptor-mediated vasorelaxationis changed by altering G protein receptorkinase 2 expression. Vascul Pharmacol2011; 55: 178-188.
10. Gros R, Chorazyczewski J, Meek MD, BenovicJL, Ferguson SS, Feldman RD: G-protein-coupled receptor kinase activity in hypertension:increased vascular and lymphocyteG-protein receptor kinase-2 proteinexpression. Hypertension 2000; 35: 38-42.
11. Belmonte SL, Blaxall BC: G protein coupledreceptor kinases as therapeutic targets in cardiovasculardisease. Circ Res 2011; 109: 309-319.
12. Oliver E, Marti D, Monto F, Flacco N, MorenoL, Barettino D, Ivorra MD, D'Ocon P: Theimpact of alpha1-Adrenoceptors up-regulationaccompanied by the impairment of betaadrenergicvasodilation in hypertension. JPharmacol Exp Ther 2009; 328: 982-990.
13. Ribeiro MO, Antunes E, de Nucci G, LovisoloSM, Zatz R: Chronich inhibition of nitric oxidesynthesis: a new model of arterial hypertension. Hypertension 1992; 20: 298-303.
14. Linardi A, Panunto PC, Ferro ES, Hyslop S:Peptidase activities in rats treated chronicallywith N(omega)-nitro-L-Arginine methyl ester( L-NAME). Biochem Pharmacol 2004; 68:205-214.
15. Marti D, Miquel R, Ziani K, Gisbert R, IvorraMD, Anselmi E, Moreno L, Villagrasa V, BarettinoD, D'Ocon P: Correlation betweenRNA levels and functional role of alpha1-Adrenoceptorsubtypes in arteries: evidence ofalpha 1A-Adrenoceptor. Am J Phyisiol HeartCirc Physiol 2005; 289:H1923-H1932.
16. Livak KJ, Schmittgen TD: Analysis of relativegene expression data using real real-timequantitative PCR and the 2(-delta delta C(T))method. Methods 2001; 25: 402-408.
17. Bradford MM: A rapid and sensitive methodfor the quantitation of microgram quantitiesof protein utilizing the principle of proteindyebinding. Annal Biochem 1976; 72: 248-254.
18. Laemmli UK: Cleavage of structural proteinsduring the assembly of the head of bacteriophageT4. Nature 1979; 227: 680-685.
19. Mulvany MJ, Halpern W: Contractile propertiesof small arterial resistance vessels in spontaneouslyhypertensive and normotensiverats. Circ Res 1977; 41: 19-26.
20. Heijenbrok FJ, Mathy MJ, Pfaffendorf M, vanZwieten PA: The influence of chronic inhibitionof nitric oxide synthesis on contractileand relaxant properties of rat carotid andmesenteric arteries. Naunyn SchmiedebergsArch Pharmacol 2000; 362: 504-511.
21. Vanhoutte PM: Endothelial dysfunction andvascular pathology. Bull Mem Acad R MedBelg 2006; 161: 529-536.
22. Vanhoutte PM, Shimokawa H, Tang EH,Feletou M: Endothelial dysfunction and vasculardisease. Acta Physiol 2009; 196: 93-222.
23. Feletou M, Verbeuren TJ, Vanhoutte PM: Endothelium-dependent contractions in SHR: atale of prostanoid TP and IP receptors. Br JPharmacol 2009; 156: 563-574.
24. Feletou M, Kohler R, Vanhoutte PM: Endothelium-derived vasoactive factors and hypertension:possible roles in pathogenesis andas treatment targets. Curr Hypertens Rep2010; 12: 267-275.
25. Porteri E, Rodella LF, Rezzani R, Rizzoni D,Paiardi S, De Ciuceis C, Boari GME, Foglio E,Favero G, Rizzardi N, Platto C, Rosei EA: Roleof heme oxygenase in modulating endothelialfunction in mesenteric small resistance arteriesof spontaneously hypertensive rats. ClinExp Hypertens 2009; 31: 560-571.
26. Mendizabal Y, Llorens S, Nava E: Reactivity ofthe aorta and mesenteric resistance arteriesfrom the obese spontaneously hypertensiverat: effects of glitazones. Am J Physiol HeartCirc Physiol 2011; 301:H1319-H1330.
27. Moncada S, Palmer RM, Higgs EA: Nitric oxide:physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
28. Chataigneau T, Feletou M, Huang PL, FishmanMC, Duhault J, Vanhoutte PM: Acetylcholine-induced relaxation in blood vesselsfrom endothelial nitric oxide synthaseknockout mice. Br J Pharmacol 1999; 126:219-226.
29. Beny JL, Nguyen MN, Marino M, Matsui M:Muscarinic receptor knockout mice confirminvolvement of M3 receptor in endotheliumdependentvasodilation in mouse arteries. JCardiovasc Pharmacol 2008; 51: 505-512.
30. Scotland RS, Chauhan S, Vallance PJ, AhluwaliaA: An endothelium-derived hyperpolarizingfactor-like factor moderates myogenicconstriction of mesenteric resistance arteriesin the absence of endothelial nitric oxidesynthase-derived nitric oxide. Hypertension2009; 38: 833-839.
31. Jin X, Satoh-Otonashi Y, Zamami Y, TakatoriS, Hashikawa-Hobara N, Kitamura Y, KawasakiH: New molecular mechanisms for cardiovasculardisease: contribution of endothelium-derived hyperpolarizing factor in theregulation of vasoconstriction in peripheralresistance arteries. J Pharmacol Sci 2011; 116:332-336.
32. Andrews KL, Irvine JC, Tare M, ApostolopoulosJ, Favaloro JL, Triggle CR, Kemp-Harper BK: A role for nitroxyl (HNO) as anendothelium-derived relaxing and hyperpolarizingfactor in resistance arteries. Br J Pharmacol2009; 157: 540-550.
33. Ingram DG, Newcomer SC, Price EM, EklundKE, McAllister RM, Laughlin MH: Chronicnitric oxide synthase inhibition blunts endothelium-dependent function of conduit coronaryarteries, not arterioles. Am J PhysiolHeart Circ Physio 2009; 292:H2798-H2808.
34. Gisbert R, Ziani K, Miquel R, Noguera MA,Ivorra MD, Anselmi E, D'Ocon P: Pathologicalrole of a constitutively active population ofalpha1D-Adrenoceptors in arteries of spontaneouslyhypertensive rats. Br J Pharmacol2002; 135: 206-216.
35. Gisbert R, Noguera MA, Ivorra MD, D'OconP: Functional evidence of a constitutively activepopulation of alpha(1D)-Adrenoceptorsin rat aorta. J Pharm Exp Ther 2000; 295: 810-817.
36. Ziani K, Gisbert R, Noguera MA, Ivorra MD,D'Ocon P: Modulatory role of a constitutivelyactive population of α 1D-Adrenoceptors inconductance arteries. Am J Physiol Heart CircPhysiol 2002; 282:H475-H481.
37. Gisbert R, Madrero Y, Sabino V, NogueraMA, Ivorra MD, D'Ocon P: Functional characterizationof alpha 1-Adrenoceptor subtypesin vascular tissues using different experimentalapproaches: a comparative study. Br JPharmacol 2003; 138: 359-368.
38. Minneman KP, Theroux TL, Hollinger S, HanC, Esbenshade TA: Selectivity of agonists forcloned alpha 1-Adrenergic receptor subtypes. Mol Pharmacol 1994; 46: 929-936.
39. Akinaga J, Lima V, Kiguti LR, Hebeler-BarbosaF, Alcantara-Hernandez R, Garcia-SainzJA, Pupo AS: Differential phosphorylation,desensitization, and internalization of α1Aadrenoceptorsactivated by norepinephrineand oxymetazoline. Mol Pharmacol 2013; 83:870-881.
40. Feldman RD, Gros R: Impaired vasodilatorfunction in hypertension: the role of alterationsin receptor-G protein coupling. TrendsCardiovasc Med 1998; 8: 297-305.
41. Ferro A, Coash M, Yamamoto T, Rob J, Ji Y,Queen L: Nitric oxide-dependent beta2-Adrenergicdilatation of rat aorta is mediatedthrough activation of both protein kinase Aand Akt. Br J Pharmacol 2004; 143: 397-403.
42. Flacco N, Segura V, Perez-Aso M, Estrada S,Seller JF, Jimenez-Altayo F, Noguera MA,D'Ocon P, Vila E, Ivorra MD: Different β-Adrenoceptorsubtypes coupling to cAMP or NO/cGMP pathways: implications in the relaxantresponse of rat conductance and resistance vessels. Br J Pharmacol 2013; 169: 413-425.
43. Brawley L, Shaw AM, Macdonald A: Beta1-,beta2-And atypical beta-Adrenoceptor-mediatedrelaxation in rat isolated aorta. Br J Pharmacol2006; 129: 637-644.
44. Briones AM, Daly CJ, Jimenez-Altayo F, Martinez-Revelles S, Gonzalez JM, McGrath JC,Vila E: Direct demonstration of β1-And evidenceagainst β2-And β3-Adrenoceptors, insmooth muscle cells of rat small mesentericarteries. Br J Pharmacol 2005; 146: 679-691.
45. Liu S, Premont RT, Kontos CD, Zhu S, RockeyDC: A crucial role for GRK2 in regulationof endothelial cell nitric oxide synthase functionin portal hypertension. Nat Med 2005; 11:952-958.
46. Cohn HI, Harris DM, Pesant S, Pfeiffer M,Zhou R, Koch WJ, Dorn GW, Eckhart AD:Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances α 1D-Adrenergic receptor constriction. Am J PhysiolHeart Circ Physiol 2008; 295:H1695-H1704.
47. Moncada S, Higgs EA: The discovery of nitricoxide and its role in vascular biology. Br JPharmacol 2006; 147:S193-S201.
48. Vallance P, Collier J, Moncada S: Effects ofendothelium-derived nitric oxide on peripheralarteriolar tone in man. Lancet 1989; 2:997-1000.